Catalogo Articoli (Spogli Riviste)

OPAC HELP

Titolo:
A comparison of dopamine agonists and catechol-O-methyltransferase inhibitors in Parkinson's disease
Autore:
Inzelberg, R; Carasso, RL; Schechtman, E; Nisipeanu, P;
Indirizzi:
Hillel Yaffe Med Ctr, Dept Neurol, IL-38100 Hadera, Israel Hillel Yaffe Med Ctr Hadera Israel IL-38100 rol, IL-38100 Hadera, Israel Technion Israel Inst Technol, Bruce Rappaport Fac Med, IL-31096 Haifa, Israel Technion Israel Inst Technol Haifa Israel IL-31096 L-31096 Haifa, Israel Israel Inst Technol, Haifa, Israel Israel Inst Technol Haifa IsraelIsrael Inst Technol, Haifa, Israel Ben Gurion Univ Negev, Dept Ind Engn & Management, IL-84105 Beer Sheva, Israel Ben Gurion Univ Negev Beer Sheva Israel IL-84105 4105 Beer Sheva, Israel
Titolo Testata:
CLINICAL NEUROPHARMACOLOGY
fascicolo: 5, volume: 23, anno: 2000,
pagine: 262 - 266
SICI:
0362-5664(200009/10)23:5<262:ACODAA>2.0.ZU;2-P
Fonte:
ISI
Lingua:
ENG
Soggetto:
PLACEBO-CONTROLLED TRIAL; DOUBLE-BLIND; MULTICENTER TRIAL; LEVODOPA; ADJUNCT;
Keywords:
Parkinson's disease; therapy; meta analysis; dopamine agonist; COMT inhibitor; double-blind study; odds ratio; motor fluctuation;
Tipo documento:
Review
Natura:
Periodico
Settore Disciplinare:
Life Sciences
Citazioni:
10
Recensione:
Indirizzi per estratti:
Indirizzo: Inzelberg, R Hillel Yaffe Med Ctr, Dept Neurol, IL-38100 Hadera, Israel Hillel Yaffe Med Ctr Hadera Israel IL-38100 Hadera, Israel
Citazione:
R. Inzelberg et al., "A comparison of dopamine agonists and catechol-O-methyltransferase inhibitors in Parkinson's disease", CLIN NEUROP, 23(5), 2000, pp. 262-266

Abstract

To compare the efficacy and tolerability of three dopamine agonists-pergolide (PRG), pramipexole (PRX), and ropinirole (ROP)-and two catechol-O-methyrtranferase (COMT) inhibitors-tolcapone (TOL) and entacapone (ENT)-as add-on therapies to levodopa (L-Dopa) in Parkinson's disease, we analyzed randomized, double-blind, placebo-controlled, multicenter studies. To our knowledge, they had not yet been evaluated in comparison with each other. Statistical analyses used odds ratios, numbers needed to harm, and Fisher's inversechi (2) method. Seven studies meeting the inclusion criteria included treatment of 1,756 patients. The common efficacy measures were the reduction ofL-Dopa dose and "off duration. The reported reduction in L-Dopa dose was significant for all drugs in relation to placebo, but was mast significant for PRX and ENT (p < 0.0001). The most significant reduction in "off" duration was with PRG, PRX, and ENT (p < 0.001). The common tolerability measureswere the percentage of patients withdrawn because of side effects, becauseof any reason, and because of the development of dyskinesias. Ropinirole, PRY, and ENT caused fewer withdrawals related to side effects. Pergolide was better than other analyzed drugs concerning withdrawals for any reason. All drugs caused more dyskinesias than placebo (p < 0.0001), with overlapping confidence intervals, except for TOL 600 mg, which caused more dyskinesias than dopamine agonists and ENT. Pramipexole and ENT had the best efficacyand tolerability profile in this analysis.

ASDD Area Sistemi Dipartimentali e Documentali, Università di Bologna, Catalogo delle riviste ed altri periodici
Documento generato il 18/09/20 alle ore 14:56:27